Real world treatment of juvenile-onset systemic lupus erythematosus: Data from the UK JSLE cohort study
Sridhar, Arani
Sridhar, Arani
Abstract
Background: In the absence of clinical trials evidence, Juvenile-onset Systemic Lupus Erythematosus (JSLE) treatment plans vary.
Aim: To explore 'real world' treatment utilising longitudinal UK JSLE Cohort Study data.
Methods: Data collected between 07/2009-05/2020 was used to explore the choice/sequence of immunomodulating drugs from diagnosis. Multivariate logistic regression determined how organ-domain involvement (pBILAG-2004) impacted treatment choice.
Result: 349 patients met inclusion criteria, median follow-up 4-years (IQR:2,6). Mycophenolate mofetil (MMF) was most commonly used for the majority of organ-domains, and significantly associated with renal involvement (OR:1.99, 95% CI:1.65-2.41, pc < 0.01). Analyses assessing the sequence of immunomodulators focused on 197/349 patients (meeting relevant inclusion/exclusion criteria). 10/197 (5%) solely recieved hydroxychloroquine/prednisolone, 62/197 (31%) received a single-immunomodulator, 69/197 (36%) received two, and 36/197 patients (28%) received ≥three immunomodulators. The most common first and second line immunomodulator was MMF. Rituximab was the most common third-line immunomodulator.
Conclusions: Most UK JSLE patients required ≥two immunomodulators, with MMF used most commonly.
MIDER Authors
Affiliations
Citations
Altmetric:
Date
2022-06
Type
Article
Collections
Citation
Smith, E. M. D., Egbivwie, N., Jorgensen, A. L., Ciurtin, C., Al-Abadi, E., Armon, K., Bailey, K., Brennan, M., Gardner-Medwin, J., Haslam, K., Hawley, D. P., Leahy, A., Leone, V., Malik, G., McLaren, Z., Pilkington, C., Ramanan, A. V., Rangaraj, S., Ratcliffe, A., Riley, P., … Hedrich, C. M. (2022). Real world treatment of juvenile-onset systemic lupus erythematosus: Data from the UK JSLE cohort study. Clinical immunology (Orlando, Fla.), 239, 109028. https://doi.org/10.1016/j.clim.2022.109028